Hospitals spent about 7% of annual pharmaceutical spend on infectious disease treatments, according to a Vizient report released July 30.
To evaluate drug expenditure in healthcare, Vizient collected medication spend data from its pharmacy program clients, including hospital, non-acute and pediatric care providers. The information below spans from April 2023 to March 2024.
The top 10 infectious disease treatments by spend, along with their approved indications:
1. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) — HIV-1
2. Prevnar 20 (pneumococcal 20-valent vaccine) — Prevention of pneumococcal disease
3. Veklury (remdesivir) — COVID-19
4. Gardasil 9 (human papillomavirus vaccine, 9-valent vaccine) — Prevention of HPV disease
5. Epclusa (sofosbuvir/velpatasvir) — Hepatitis C
6. Xifaxan (rifaximin) — Traveler's diarrhea, hepatic encephalopathy
7. Shingrix — Prevention of herpes zoster
8. Mavyret (glecaprevir/pibrentasvir) — Hepatitis C
9. Boostrix — Prevention of diphtheria, pertussis, tetanus
10. Ambisome (amphotericin B liposome) — Fungal infections